Tan Jack Wei Chieh, Chew Derek P, Brieger David, Eikelboom John, Montalescot Gilles, Ako Junya, Kim Byeong-Keuk, Quek David Kl, Aitken Sarah J, Chow Clara K, Chour Sok, Tse Hung Fat, Kaul Upendra, Firdaus Isman, Kubo Takashi, Liew Boon Wah, Chong Tze Tec, Sin Kenny Yk, Yeh Hung-I, Buddhari Wacin, Chunhamaneewat Narathip, Hasan Faisal, Fox Keith Aa, Nguyen Quang Ngoc, Lo Sidney Th
National Heart Centre Singapore.
Sengkang General Hospital Singapore.
Eur Cardiol. 2021 Jun 18;16:e26. doi: 10.15420/ecr.2020.45. eCollection 2021 Feb.
The unique characteristics of patients with chronic coronary syndrome (CCS) in the Asia-Pacific region, heterogeneous approaches because of differences in accesses and resources and low number of patients from the Asia-Pacific region in pivotal studies, mean that international guidelines cannot be routinely applied to these populations. The Asian Pacific Society of Cardiology developed these consensus recommendations to summarise current evidence on the management of CCS and provide recommendations to assist clinicians treat patients from the region. The consensus recommendations were developed by an expert consensus panel who reviewed and appraised the available literature, with focus on data from patients in Asia-Pacific. Consensus statements were developed then put to an online vote. The resulting recommendations provide guidance on the assessment and management of bleeding and ischaemic risks in Asian CCS patients. Furthermore, the selection of long-term antithrombotic therapy is discussed, including the role of single antiplatelet therapy, dual antiplatelet therapy and dual pathway inhibition therapy.
亚太地区慢性冠状动脉综合征（CCS）患者具有独特特征，由于医疗可及性和资源存在差异导致方法各异，且关键研究中来自亚太地区的患者数量较少，这意味着国际指南无法常规应用于这些人群。亚太心脏病学会制定了这些共识性建议，以总结CCS管理的当前证据，并提供建议以协助临床医生治疗该地区的患者。这些共识性建议由一个专家共识小组制定，该小组对现有文献进行了审查和评估，重点关注来自亚太地区患者的数据。随后制定了共识声明并进行在线投票。所得建议为评估和管理亚洲CCS患者的出血和缺血风险提供了指导。此外，还讨论了长期抗栓治疗的选择，包括单一抗血小板治疗、双联抗血小板治疗和双途径抑制治疗的作用。
